Contract drugmaker Catalent shows signs of recovery in Q1 revenue beat
(Reuters) -Catalent beat Wall Street's estimates for first-quarter revenue on Wednesday, as the contract drug manufacturer showed signs of improvement
1970-01-01 08:00
Catalent delays quarterly filing with SEC on $700 million impairment charge
Catalent will delay its quarterly filing with the U.S. securities regulator due to a goodwill impairment charge of
1970-01-01 08:00
Catalent revenue falls, delays annual report
Catalent Inc reported a 17% fall in quarterly revenue on Tuesday, hurt by persistent production-related challenges at the
1970-01-01 08:00
Exclusive-Catalent nears settlement with Elliott for board seats -sources
By Svea Herbst-Bayliss and Maggie Fick Catalent Inc is close to reaching a settlement with Elliott Investment Management
1970-01-01 08:00
Catalent, facing pressure from Elliott, had other activists in stock
By Svea Herbst-Bayliss NEW YORK Contract drugmaker Catalent, which is being pushed to make changes to its board
1970-01-01 08:00
Activist investor Elliott takes big stake in drugmaker Catalent - WSJ
Activist investor Elliott Investment has built a significant stake in Catalent and is pushing for a shake-up on
1970-01-01 08:00
Catalent reports bigger-than-expected loss on production challenges
(Reuters) -Catalent Inc on Monday posted a bigger-than-expected loss for the third quarter, hurt by persistent production challenges at the
1970-01-01 08:00